Conversion Liver Resection for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus after Single Tremelimumab Regular Interval Durvalumab Regimen as a Second-Line Therapy: A Case Report

INTRODUCTION: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with limited treatment options for advanced, unresectable cases. Although immune checkpoint inhibitors (ICI), particularly the combination of atezolizumab plus bevacizumab (Atezo+Bev), have improved outcomes, many patients ultimately experience disease progression. The single tremelimumab regular interval durvalumab (STRIDE) regimen has emerged as a promising alternative, yet evidence of its efficacy as a second-line therapy remains limited.